Diabetes is a condition with abnormally high level of insulin in blood. Diabetes Drugs are used to treat diabetes mellitus by lowering the glucose levels in the blood. Type 1 Diabetes is a condition caused by the lack of insulin, whereas Type 2 Diabetes is a condition caused due to insulin resistance by cells. The approvals of new drugs such as Canagliflozin and dapagliflozin for the treatment of diabetes, would create numerous opportunities for new as well as existing players in the global diabetes drugs market. The increasing diabetic population, technological innovations and the increasing adoption rate in developing regions are the key factors, which would drive the growth of global diabetes drugs market over the analysis period. Two major factors that restrain the market growth are stringent regulatory environment and time consuming approval process.

The global diabetes drugs market, is segmented on the basis of Drug type, Application and Geography. The drug types considered, in this report include Injectable Drugs and Oral Drugs. Injectable drugs are further classified into Insulin, Exenatide, Liragultide and Pramlintide. Oral drugs are further classified into Biguanides, Sulfonylureas, Meglitinides and D-Phenylalanine Derivatives, Thiazolidinediones, DPP-4 Inhibitors, Alpha-glucosidase Inhibitors, Bile Acid Sequestrants and Others. (Combination Pills). Based on application, the global diabetes drugs market is classified into Type 1 Diabetes and Type 2 diabetes. Geographically, the report is segmented across four regions namely North America, Europe, Asia Pacific and LAMEA. One of the strategies adopted by major market players is product launch. For instance, recently in 2015, Novo Nordisk launched the diabetes drug Ryzodeg in India. This drug, which requires fewer injections, has helped the company (Novo Nordisk) to efficiently cater to a large diabetic population base in India. The companies profiled in this report are Abbott laboratories, Bayer healthcare, Biocon ltd, Bristol-Myers Squibb, Dr. Reddy's laboratories ltd, Eli lilly and company, Glaxosmithkline, Lupin ltd, Piramal healthcare ltd and Ranbaxy laboratories ltd.

KEY MARKET BENEFITS:

• The report provides a quantitative analysis of the current market and estimations through 2014-2020, which would enable the stakeholders to capitalize on prevailing market opportunities
• Extensive analysis of the global Diabetes Drugs equipment market by product type helps in understanding the types of equipment that are currently used along with the variants that would gain prominence in future
• Competitive intelligence highlights the business practices followed by leading market players across various geographies
• Comprehensive analysis of factors that drive and restrict the growth of the global Diabetes Drugs market is provided
• SWOT analysis highlights the internal environment of leading companies for effective strategy formulation
• The Diabetes Drugs market scenario is comprehensively analysed in accordance to the key regions

KEY MARKET SEGMENTS:

The Diabetes Drugs Market is segmented as below:

Diabetes Drugs Market By Drug Type

• Injectable Drugs
  • Insulin
  • Exenatide
  • Liragultide
  • Pramlintide
• Oral Drugs
  • Biguanides
  • Sulfonylureas
  • Meglitinides and D-Phenylalanine Derivatives
  • Thiazolidinediones
  • DPP-4 Inhibitors
  • Alpha-glucosidase Inhibitors
  • Bile Acid Sequestrants
  • Others (Combination Pills)

Diabetes Drugs Market By Application

• Type 1 Diabetes
• Type 2 Diabetes

Diabetes Drugs Market By Geography

• North America
• Europe
• Asia Pacific
• LAMEA

 Key Market Segments

 
Key Market Players

• Abbott laboratories
• Bayer healthcare
• Biocon ltd
• Bristol-Myers Squibb
• Dr. Reddy's laboratories ltd
• Eli lilly and company
• Glaxosmithkline
• Lupin ltd
• Piramal healthcare ltd
• Ranbaxy laboratories ltd.